Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Vaxart, Inc. (NASDAQ:VXRT) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.73 and traded as low as $0.59. Vaxart shares last traded at $0.62, with a volume of 1,568,544 shares changing hands.

Vaxart Price Performance

The stock has a market capitalization of $140.95 million, a P/E ratio of -1.51 and a beta of 0.62. The stock’s fifty day moving average is $0.68 and its 200-day moving average is $0.73.

Institutional Investors Weigh In On Vaxart

A number of large investors have recently added to or reduced their stakes in the stock. Mesirow Financial Investment Management Inc. lifted its stake in shares of Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after buying an additional 20,000 shares during the last quarter. XTX Topco Ltd raised its holdings in Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 122,387 shares during the period. Monaco Asset Management SAM acquired a new position in Vaxart during the 2nd quarter worth $402,000. Geode Capital Management LLC lifted its position in Vaxart by 15.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after acquiring an additional 346,725 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Vaxart by 110.8% during the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after acquiring an additional 2,095,274 shares during the period. Institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.